The FDA’s new AI chatbot for approving drugs is not quite hitting the mark

The FDA’s New AI Tool Sparks Concerns

The Food and Drug Administration’s (FDA) new AI tool, named Elsa, was introduced with the promise of revolutionizing drug approvals. However, initial reports suggest that the tool is causing more confusion than solutions. FDA insiders have anonymously shared that the chatbot frequently hallucinates, providing incorrect information and misinterpreting important data.

The FDA’s head of AI and Commissioner have acknowledged the tool’s shortcomings and emphasized the need for further testing and training. Despite the tool’s integration into organizational duties, it is not required for employees working on clinical reviews. The FDA has faced criticism for its reliance on AI technology in crucial decision-making processes.

Trump Administration’s Aggressive AI Agenda

The Trump administration has pushed for an accelerated AI agenda, aiming to establish FDA-backed AI Centers of Excellence for testing and deploying new AI tools. This aggressive approach has raised concerns about the lack of oversight and regulation in the adoption of AI technology, particularly in critical sectors like healthcare.

The government’s AI Action Plan emphasizes the need for a coordinated federal effort to promote the adoption of AI across various industries. However, critics argue that the rush to embrace AI may overlook the risks and challenges associated with its implementation.

Topics: Artificial Intelligence, Health, Social Good.